Search results

  1. Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma.

    Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphoma. Journal …

  2. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study.

    … rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. …

  3. BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.

    … untreated, transplant-ineligible patients with mantle cell lymphoma. Journal …

  4. Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.

    … of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study. …

  5. The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool.

    … The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an …

  6. CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL.

    CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone …

  7. Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.

    … of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies. …

  8. Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada.

    … Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. Journal …

  9. Erratum to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome.

    … to: DUSP22-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have …

  10. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.

    … Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. Journal …

Back to top